Compare CSTE & PDSB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CSTE | PDSB |
|---|---|---|
| Founded | 1987 | 2005 |
| Country | Israel | United States |
| Employees | N/A | 10 |
| Industry | Building Materials | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 66.7M | 62.0M |
| IPO Year | 2012 | 2015 |
| Metric | CSTE | PDSB |
|---|---|---|
| Price | $1.78 | $1.12 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 163.0K | ★ 1.1M |
| Earning Date | 05-13-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 28.16 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $3.43 | N/A |
| Revenue Next Year | $2.83 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.56 | $0.51 |
| 52 Week High | $2.58 | $1.85 |
| Indicator | CSTE | PDSB |
|---|---|---|
| Relative Strength Index (RSI) | 53.76 | 51.45 |
| Support Level | $1.42 | $0.91 |
| Resistance Level | $1.76 | $1.40 |
| Average True Range (ATR) | 0.12 | 0.13 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 19.74 | 51.04 |
Caesarstone Ltd manufactures engineered quartz surfaces. Its products include engineered quartz and porcelain slabs, which are used as kitchen countertops in renovation and remodeling, and residential construction. It also has other applications, including vanity tops, wall panels, backsplashes, floor tiles, stairs, and other interior surfaces that are used in various residential and non-residential applications. The company sells its products under the Caesarstone brand. Caesarstone's geographical segments are the United States, Canada, Latin America, Australia, Asia, Israel, and EMEA(Europe, Middle East, Africa), of which it derives maximum revenue from United States.
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells. The company has determined that it operates as a single reportable segment, developing a growing pipeline of targeted immunotherapies designed to overcome the limitations of current immunotherapy.